Skip to Content

Join the 'Dalfampridine' group to help and get support from people like you.

Dalfampridine News

FDA Medwatch Alert: Ampyra (dalfampridine): Drug Safety Communication - Seizure Risk for Multiple Sclerosis Patients

Posted 23 Jul 2012 by Drugs.com

ISSUE: FDA is updating health care professionals and the public about the risk of seizures in patients with multiple sclerosis (MS) who are starting Ampyra (dalfampridine). Using information received from post-market adverse event reports, FDA recently evaluated seizure risk in MS patients taking Ampyra (dalfampridine).  The majority of seizures happened within days to weeks after starting the ...

Ask a Question

Further Information

Related Condition Support Groups

Multiple Sclerosis

Related Drug Support Groups

Ampyra

Dalfampridine Patient Information at Drugs.com